Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc. has announced the start of a global and comprehensive strategy to expand the company's primary focus and re-engineer psychedelic treatment services offered throughout North America.
The strategy, planned by its recently appointed CEO, Najla Guthrie, will seek to establish next-generation mental health clinics, contemporize existing clinic facilities and launch best-in-class adjunct programs to improve patient treatment outcomes.
"The evidence shows that patient access to mental healthcare remains one of the primary issues of the mental health crisis. Both the psychedelic medicine and digital therapeutics sectors are moving at light speed to address this, but they face two major obstacles; clinical development to gain regulatory approvals, and clinical adoption by the medical establishment,” Guthrie said in a statement.
READ: Wellbeing Digital Sciences welcomes Najla Guthrie as its new CEO
“Wellbeing provides a solution to both of these problems faced by industry, which more importantly allows us to provide our patients with early access to life-saving treatments," added Guthrie.
The comprehensive plan is expected to bolster Wellbeing's goal of becoming the healthcare model of choice in North America for the treatment of mental illnesses.
Wellbeing said it aims to conduct contract research and provide novel technology-enabled solutions backed by scientific evidence to clinics around North America, by using digital therapeutics to complement physical therapy, psychotherapy, pain management and psychedelic-based treatments.
It also intends to create a contemporary network of collaborating clinicians to bring forth the best mental health services under its re-conceptualized plan.
"We are passionate about being part of the evolution to foster initial change in the current mental health system and re-evaluate future change through our Wellbeing expert network. By incorporating these changes to differentiate our ability to improve mental health outcomes, we look forward to demonstrating the positive impact we are creating in patients through clinical research. As the driver of innovative change in how mental health care is delivered in the future, we create value for our patients, clinician network, shareholders, and stakeholders," Guthrie concluded.
Contact the author at jon.hopkins@proactiveinvestors.com